AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15792400 — intervention group
Group type: COMPARATOR
Intervention: Commercial 250 mg nelfinavir tablet (reference formulation)
Number of subjects: 52
Study 12851606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with or without abciximab
Number of subjects: 878
Study 12851606 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 878
Study 10533870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate with chlorofluorocarbons as propellant
Number of subjects: 0
Study 10533870 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate with hydrofluoroalkane as propellant
Number of subjects: 0
Study 2196670 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin 200 mg twice daily for 7 days
Number of subjects: 343
Study 2196670 — intervention group
Group type: COMPARATOR
Intervention: pivmecillinam 200 mg 3 times daily for 7 days
Number of subjects: 343
Study 351715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine and prostaglandin A1 administered conjointly
Number of subjects: 6
Study 351715 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin A1
Number of subjects: 6
Study 351715 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 6
Study 351715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine and prostaglandin A1
Number of subjects: 6
Study 29959667 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 25
Study 29959667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28668289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 μg every 2 h (maximum of 12 doses)
Number of subjects: 602
Study 28668289 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Foley catheter (silicone, size 18 F with 30 mL balloon)
Number of subjects: 602
Study 26484463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (N2O)
Number of subjects: 78
Study 26484463 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 78
Study 23828223 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 at 30 mg/kg
Number of subjects: 52
Study 23828223 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 at 40 mg/kg
Number of subjects: 52
Study 23828223 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 at 50 mg/kg
Number of subjects: 52
Study 23828223 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 plus hydroxyurea
Number of subjects: 52
Study 23828223 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001
Number of subjects: 52
Study 22859239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg at weeks 0, 4, and 16
Number of subjects: 121
Study 22859239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 22859239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 121
Study 19453319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 9
Study 19453319 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitors
Number of subjects: 9
Study 17608341 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAM interspinous process spacer (Group D)
Number of subjects: 62
Study 17608341 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 62
Study 15196108 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 microg) pre-emptively
Number of subjects: 20
Study 15196108 — intervention group
Group type: COMPARATOR
Intervention: Control group (sufentanil at the end of surgery)
Number of subjects: 20
Study 15196108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 12596623 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose azithromycin prophylaxis
Number of subjects: 122
Study 12596623 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 122
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine SBP in normotensive subjects
Number of subjects: 97
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine SBP in borderline hypertensive subjects
Number of subjects: 97
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG DBP in mildly hypertensive subjects
Number of subjects: 97
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG SBP in mildly hypertensive subjects
Number of subjects: 97
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: OSBP in normotensive subjects
Number of subjects: 97
Study 9649909 — intervention group
Group type: EXPERIMENTAL
Intervention: ODB in normotensive and mildly hypertensive subjects
Number of subjects: 97
Study 8127110 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per hour)
Number of subjects: 120
Study 8127110 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1 micrograms/kg per minute)
Number of subjects: 120
Study 2567150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 60
Study 2567150 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (400 mg daily for months 0‐6, then 200 mg daily)
Number of subjects: 60
Study 2567150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 60
Study 2567150 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 60
Study 6254159 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride
Number of subjects: 75
Study 6254159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of sexual violence (SV)
Number of subjects: 836
Study 31365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual violence by age 15
Number of subjects: 836
Study 31365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with SV by a partner
Number of subjects: 836
Study 31365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with SV by a non-partner
Number of subjects: 836
Study 31365536 — intervention group
Group type: EXPERIMENTAL
Intervention: SV experiences in childhood or adulthood
Number of subjects: 836
Study 28722422 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine (MDMA)
Number of subjects: 15
Study 28722422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26545986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <125 mmHg)
Number of subjects: 83
Study 26545986 — intervention group
Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target systolic BP <140 mmHg)
Number of subjects: 83
Study 26545986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (target LDL cholesterol <1.4 mmol/L)
Number of subjects: 83
Study 26545986 — intervention group
Group type: COMPARATOR
Intervention: Guideline lipid lowering (target LDL cholesterol <3 mmol/L)
Number of subjects: 83
Study 26545986 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of performing a large trial of one or both interventions
Number of subjects: 83
Study 24180162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 60
Study 24180162 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline solution)
Number of subjects: 60
Study 22475305 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 10 μg/kg/day for 3 days
Number of subjects: 60
Study 22475305 — intervention group
Group type: COMPARATOR
Intervention: Non-G‐CSF group
Number of subjects: 60
Study 22475305 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy newborns)
Number of subjects: 60
Study 20513340 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Health Internet intervention
Number of subjects: 773
Study 17165082 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride (isoptin 240 mg KKH tablets, oral t.i.d.)
Number of subjects: 95
Study 17165082 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy (control group)
Number of subjects: 95
Study 16178942 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management plus acupuncture
Number of subjects: 74
Study 16178942 — intervention group
Group type: COMPARATOR
Intervention: Medical management only
Number of subjects: 74
Study 12174946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Doxorubicin (A) -> Docetaxel (T) -> CMF
Number of subjects: 93
Study 12174946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential accelerated A -> T -> CMF
Number of subjects: 93
Study 12174946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy: A 50 mg/m2 + T 75 mg/m2 q 3 wks x 4, followed by CMF x 4
Number of subjects: 93
Study 12174946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential T -> A -> CMF
Number of subjects: 93
Study 10545692 — intervention group
Group type: COMPARATOR
Intervention: Contralateral movement in controls
Number of subjects: 30
Study 10545692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral movement (affected hand) in patients
Number of subjects: 30
Study 10545692 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral movement (affected hand) in patients at T1 and T2
Number of subjects: 30
Study 10545692 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral movement (affected hand) in patients at T3
Number of subjects: 30
Study 8655009 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with endometriosis
Number of subjects: 0
Study 8655009 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with idiopathic infertility
Number of subjects: 0
Study 8655009 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with hypothalamic‐pituitary dysfunction
Number of subjects: 0
Study 8655009 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in healthy nonpregnant women
Number of subjects: 0
Study 8655009 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ANA with negative postcoital test and spontaneous abortions in endometriosis and idiopathic infertility
Number of subjects: 0
Study 2216006 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal hydration (Group B)
Number of subjects: 26
Study 2216006 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 26
Study 7433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg 3-times daily)
Number of subjects: 45
Study 7433479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (12-month follow-up)
Number of subjects: 45
Study 7433479 — intervention group
Group type: COMPARATOR
Intervention: Control (12-month follow-up)
Number of subjects: 45
Study 7433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 45
Study 31753880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Eating (ME) + Treatment as Usual (TAU)
Number of subjects: 76
Study 31753880 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study 28765644 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased triglycerides (TG)
Number of subjects: 14864
Study 28765644 — intervention group
Group type: EXPERIMENTAL
Intervention: TG/HDL
Number of subjects: 14864
Study 28765644 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased high density lipoprotein (HDL)
Number of subjects: 14864
Study 28765644 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677 CT genotype
Number of subjects: 14864
Study 25765294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution twice daily for 3 months
Number of subjects: 30
Study 25765294 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% cream once daily for 3 months
Number of subjects: 30
Study 23389755 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days)
Number of subjects: 48
Study 23389755 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 23389755 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study 21414978 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic attitude during preoperative visit
Number of subjects: 136
Study 21414978 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care (same anaesthesiologist for preoperative visit and anaesthesia)
Number of subjects: 136
Study 21414978 — intervention group
Group type: COMPARATOR
Intervention: Neutral attitude during preoperative visit
Number of subjects: 136
Study 21414978 — intervention group
Group type: COMPARATOR
Intervention: Divided care (preoperative visit and anaesthesia by different anaesthesiologists)
Number of subjects: 136
Study 20008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and dose‐intensified approaches including autologous stem cell transplantation (ASCT) strategies
Number of subjects: 0
Study 20008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging strategies such as proteasome inhibitors, IMIDs, mTOR inhibitors
Number of subjects: 0
Study 20008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination strategies currently being investigated in numerous trials
Number of subjects: 0
Study 18041162 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC isosorbide dinitrate/hydralazine
Number of subjects: 1050
Study 18041162 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1050
Study 18041162 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or ARBs
Number of subjects: 1050
Study 18041162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 15006575 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal stomach
Number of subjects: 44
Study 15006575 — intervention group
Group type: EXPERIMENTAL
Intervention: Slender gastric tube
Number of subjects: 44
Study 11812474 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthofix distally based distal targeting device
Number of subjects: 58
Study 11812474 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 58
Study 9164362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium nasal spray (42 micrograms per nostril, administered twice daily for 4 weeks)
Number of subjects: 202
Study 9164362 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (administered twice daily for 4 weeks)
Number of subjects: 202
Study 7956412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mechanical ventilation in the prone position
Number of subjects: 12
Study 7956412 — intervention group
Group type: COMPARATOR
Intervention: Returning the patient to the supine position
Number of subjects: 12
Study 3652627 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine therapy (1 to 6 g intravenously once a week for a mean duration of 7.6 +/- 3.3 months)
Number of subjects: 16
Study 3652627 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine therapy
Number of subjects: 16
Study 28727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 65
Study 26876735 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA files in continuous rotation
Number of subjects: 32
Study 26876735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo files in continuous rotation
Number of subjects: 32
Study 26876735 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA files in adaptive motion
Number of subjects: 32
Study 26876735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo files in adaptive motion
Number of subjects: 32
Study 26286351 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 121
Study 26286351 — intervention group
Group type: COMPARATOR
Intervention: Individual Addiction Counseling (IAC)
Number of subjects: 121
Study 23583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin antibody fragment (DIF)
Number of subjects: 36
Study 23583219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20229023 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte (CHO-E) solution
Number of subjects: 15
Study 20229023 — intervention group
Group type: COMPARATOR
Intervention: Non-carbohydrate (CHO) placebo
Number of subjects: 15
Study 16778821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 68
Study 16778821 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autograft
Number of subjects: 68
Study 15661816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum)
Number of subjects: 22
Study 15661816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with NOS inhibition (10 mm l-NAME)
Number of subjects: 22
Study 15661816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with COX inhibition (10 mm ketorolac)
Number of subjects: 22
Study 15661816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with NOS and COX inhibition
Number of subjects: 22
Study 11932074 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (20 sessions)
Number of subjects: 131
Study 11932074 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (20 sessions)
Number of subjects: 131
Study 11932074 — intervention group
Group type: COMPARATOR
Intervention: Control condition (physiotherapy)
Number of subjects: 131
Study 11081007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by an arthritis patient educator
Number of subjects: 108
Study 7864705 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 1.2 g over 20 minutes after albuterol treatment
Number of subjects: 72
Study 7864705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7864705 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 72
Study 1771089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0
Study 1771089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0
Study 1771089 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 0
Study 6185343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of methotrexate (MTX) 500 mg over 10 days
Number of subjects: 85
Study 6185343 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial infusion of bleomycin (BLM) 95 mg over 13 days
Number of subjects: 85
Study 31847208 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese girls and women (defined by BMI)
Number of subjects: 3623
Study 31847208 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with ≥30% body fat percentage (BF%)
Number of subjects: 3623
Study 30613078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound (LIUS) and traditional exercise therapy (TET)
Number of subjects: 60
Study 30613078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) and traditional exercise therapy (TET)
Number of subjects: 60
Study 30613078 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise therapy (TET)
Number of subjects: 60
Study 28779736 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% dietary lipid
Number of subjects: 225
Study 28779736 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dietary lipid
Number of subjects: 225
Study 28779736 — intervention group
Group type: COMPARATOR
Intervention: 0%, 8%, and 12% dietary lipid
Number of subjects: 225
Study 25074351 — intervention group
Group type: EXPERIMENTAL
Intervention: ibandronate 150 mg/month
Number of subjects: 172
Study 25074351 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate 70 mg/week
Number of subjects: 172
Study 25074351 — intervention group
Group type: EXPERIMENTAL
Intervention: risedronate 35 mg/week
Number of subjects: 172
Study 25074351 — intervention group
Group type: EXPERIMENTAL
Intervention: oral bisphosphonates (all three types)
Number of subjects: 172
Study 22935241 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination (SD) of a guideline package
Number of subjects: 19
Study 22935241 — intervention group
Group type: EXPERIMENTAL
Intervention: SD plus a web-based resource championed by an opinion leader
Number of subjects: 19
Study 22935241 — intervention group
Group type: EXPERIMENTAL
Intervention: SD plus plan-do-study-act (PDSA)
Number of subjects: 19
Study 19885413 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants (thin mucosa, group A)
Number of subjects: 19
Study 19885413 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants (thick mucosa, group B)
Number of subjects: 19
Study 19885413 — intervention group
Group type: COMPARATOR
Intervention: Control implants
Number of subjects: 19
Study 17163245 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20microg/drsp 3mg
Number of subjects: 516
Study 14633055 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 0
Study 14633055 — intervention group
Group type: EXPERIMENTAL
Intervention: Big-Five personality characteristics
Number of subjects: 0
Study 14633055 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreeableness and Openness
Number of subjects: 0
Study 10723632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg/20 ml
Number of subjects: 14
Study 10723632 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo infusions
Number of subjects: 14
Study 8704691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue
Number of subjects: 42
Study 8704691 — intervention group
Group type: COMPARATOR
Intervention: PBPC instead of marrow
Number of subjects: 42
Study 1735888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity arterial duplex mapping
Number of subjects: 150
Study 1735888 — intervention group
Group type: COMPARATOR
Intervention: Clinical disease category
Number of subjects: 150